Ultra-low-dose (boom-boom) radiotherapy for management of recurrent ocular post-transplant lymphoproliferative disorder

Konstantin V. Astafurov, Erick D. Bothun, Nadia N. Laack, Amanda J. Deisher, Sanjay V. Patel, Lauren A. Dalvin

Research output: Contribution to journalArticlepeer-review


Purpose: To report a case of recurrent iris post-transplant lymphoproliferative disorder (PTLD) treated with ultra-low-dose (boom-boom) radiotherapy (RT). Observations: A 12-year-old Caucasian male with a history of bilateral, recurrent iris PTLD of the extranodal marginal zone lymphoma (MALT) type presented with persistent bilateral anterior chamber cellular infiltration, which was incompletely controlled on topical corticosteroids, and with elevated intraocular pressure (IOP) in the right eye secondary to steroid response. The patient was diagnosed with PTLD recurrence and was successfully treated with ultra-low-dose RT to both eyes in 2 fractions of 2 Gy. At 15 month follow-up the patient maintained complete disease control with normal IOP off all topical ophthalmic medications. Conclusions and Importance: Ultra-low-dose RT for ocular PTLD of the MALT subtype represents a novel therapeutic approach that may provide a durable treatment response and could be considered as either primary or adjuvant therapy for this rare condition.

Original languageEnglish (US)
Article number101118
JournalAmerican Journal of Ophthalmology Case Reports
StatePublished - Sep 2021


  • Boom-boom radiotherapy
  • Iris
  • Marginal zone lymphoma
  • Ocular
  • Post-transplant lymphoproliferative disorder
  • Ultra-low-dose radiation therapy

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Ultra-low-dose (boom-boom) radiotherapy for management of recurrent ocular post-transplant lymphoproliferative disorder'. Together they form a unique fingerprint.

Cite this